Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
Top Cited Papers
- 25 April 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 135 (17) , e927-e999
- https://doi.org/10.1161/cir.0000000000000484
Abstract
Background: Kawasaki disease is an acute vasculitis of childhood that leads to coronary artery aneurysms in ≈25% of untreated cases. It has been reported worldwide and is the leading cause of acquired heart disease in children in developed countries. Methods and Results: To revise the previous American Heart Association guidelines, a multidisciplinary writing group of experts was convened to review and appraise available evidence and practice-based opinion, as well as to provide updated recommendations for diagnosis, treatment of the acute illness, and long-term management. Although the cause remains unknown, discussion sections highlight new insights into the epidemiology, genetics, pathogenesis, pathology, natural history, and long-term outcomes. Prompt diagnosis is essential, and an updated algorithm defines supplemental information to be used to assist the diagnosis when classic clinical criteria are incomplete. Although intravenous immune globulin is the mainstay of initial treatment, the role for additional primary therapy in selected patients is discussed. Approximately 10% to 20% of patients do not respond to initial intravenous immune globulin, and recommendations for additional therapies are provided. Careful initial management of evolving coronary artery abnormalities is essential, necessitating an increased frequency of assessments and escalation of thromboprophylaxis. Risk stratification for long-term management is based primarily on maximal coronary artery luminal dimensions, normalized as Z scores, and is calibrated to both past and current involvement. Patients with aneurysms require life-long and uninterrupted cardiology follow-up. Conclusions: These recommendations provide updated and best evidence-based guidance to healthcare providers who diagnose and manage Kawasaki disease, but clinical decision making should be individualized to specific patient circumstances.Keywords
This publication has 394 references indexed in Scilit:
- Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki diseaseJournal of Allergy and Clinical Immunology, 2011
- Ventricular Repolarization Lability in Children With Kawasaki DiseasePediatric Cardiology, 2011
- Noncoronary Cardiac Abnormalities Are Associated With Coronary Artery Dilation and With Laboratory Inflammatory Markers in Acute Kawasaki DiseaseJournal of the American College of Cardiology, 2011
- Predictors of Coronary Artery Visualization in Kawasaki DiseaseJournal of the American Society of Echocardiography, 2011
- Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki DiseaseThe Journal of Pediatrics, 2010
- When Children With Kawasaki Disease Grow Up: Myocardial and Vascular Complications in AdulthoodPublished by Elsevier ,2009
- Associated Symptoms in the Ten Days Before Diagnosis of Kawasaki DiseaseThe Journal of Pediatrics, 2008
- Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki DiseaseThe Journal of Pediatrics, 2008
- Resistance to Intravenous Immunoglobulin in Children with Kawasaki DiseaseThe Journal of Pediatrics, 2008
- Arthritis presenting during the acute phase of Kawasaki diseaseThe Journal of Pediatrics, 2006